Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2005
Does transesophageal echocardiographic demonstration of a patent foramen ovale in patients with a recent cerebral ischemic event change anticoagulation therapy?
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boddicker Kimberly A, Kerber Richard E
Аннотация
BACKGROUND: Patent foramen ovale (PFO) is commonly demonstrated by transesophageal echocardiography (TEE) in patients with a recent transient ischemic attack or stroke. Our purpose was to determine how the TEE visualization of a PFO alters anticoagulation therapy.
METHODS: We retrospectively identified 100 patients with transient ischemic attack or stroke referred for TEE; 50 had a PFO and 50 did not (control patients).
RESULTS: Both groups were similar in regard to age, sex, the occurrence of transient ischemic attack versus stroke, and history of stroke. The PFO group had a higher incidence of a mobile interatrial septum, interatrial septal aneurysm, or both ( P < .001 by Fisher exact test). Both groups had similar pre-TEE aspirin, other antiplatelet, and warfarin use. After TEE, warfarin was instituted in 8 of 50 patients with PFO versus 2 of 50 in the control group ( P = .05) and aspirin use was discontinued in 9 of 50 patients with PFO versus 3 of 50 in the control group ( P = .12).
CONCLUSION: The main effect of demonstrating a PFO by TEE after an ischemic cerebral event was the institution of warfarin; there was a trend toward discontinuing aspirin.
METHODS: We retrospectively identified 100 patients with transient ischemic attack or stroke referred for TEE; 50 had a PFO and 50 did not (control patients).
RESULTS: Both groups were similar in regard to age, sex, the occurrence of transient ischemic attack versus stroke, and history of stroke. The PFO group had a higher incidence of a mobile interatrial septum, interatrial septal aneurysm, or both ( P < .001 by Fisher exact test). Both groups had similar pre-TEE aspirin, other antiplatelet, and warfarin use. After TEE, warfarin was instituted in 8 of 50 patients with PFO versus 2 of 50 in the control group ( P = .05) and aspirin use was discontinued in 9 of 50 patients with PFO versus 3 of 50 in the control group ( P = .12).
CONCLUSION: The main effect of demonstrating a PFO by TEE after an ischemic cerebral event was the institution of warfarin; there was a trend toward discontinuing aspirin.